Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

DBV Technologies (DBVT): which funds own it

Health Care →Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow DBVT for free
Share

Sections with a free account

8 concentrated managers hold it (+2 vs last quarter) with a median weight of 0.6%.

Who owns DBV Technologies?

DBV Technologies trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): Baker Bros. Advisors, 10.0% (13D/A filed Jan 14, 2026), Montanova Capital, 9.9% (13G filed Apr 11, 2025), Adage Capital Management, 7.3% (13G/A filed May 13, 2026), Raymond Debbane, 6.5% (13G/A filed May 5, 2026) and Citadel Advisors, 6.4% (13G filed Apr 14, 2025). As of Jun 30, 2026, the largest ADR holders reported on Form 13F were MPM Bioimpact (3.7 million ADRs), Siren, L.L.C (1.9 million ADRs) and Vivo Capital (1.8 million ADRs).

Which institutions hold the most DBV Technologies shares?

Per Form 13F filings as of Jun 30, 2026, in ADRs:

  1. 1. MPM Bioimpact: 3.7 million ADRs
  2. 2. Siren, L.L.C: 1.9 million ADRs
  3. 3. Vivo Capital: 1.8 million ADRs
  4. 4. Perceptive Advisors: 1.7 million ADRs
  5. 5. Baker Bros. Advisors: 1.5 million ADRs
  6. 6. Artisan Partners Limited Partnership: 1.4 million ADRs
  7. 7. UBS Group: 1.3 million ADRs
  8. 8. Morgan Stanley: 954,908 ADRs
  9. 9. Logos Global Management: 915,000 ADRs
  10. 10. Patient Square Capital: 909,474 ADRs

Sources:13D/A by Baker Bros. Advisors (Jan 14, 2026) ↗13G by Montanova Capital (Apr 11, 2025) ↗13G/A by Adage Capital Management (May 13, 2026) ↗13G/A by Raymond Debbane (May 5, 2026) ↗13G by Citadel Advisors (Apr 14, 2025) ↗All of the company's proxy statements on EDGAR ↗

We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

DBV Technologies revenue

DBV Technologies reported annual revenue of $5.6 million for fiscal year 2025 (year ended December 31, 2025), according to its Form 10-K filed with the SEC (XBRL data).

Well-known investors holding it

Stanley Druckenmiller 13F (Q2 2026)

Concentrated managers
8
All 13F: 80
Consensus
17/100
across 8 concentrated managersRanks by accumulation, portfolio weight and number of managers; it does not say more are buying than selling.
Price at Jun 30, 2026 (per 13F)
$16.4
-21.5% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (6 → 8): 2 opened · 0 exited = +2

Net flow in the quarter: −$22.6M (−1.4 M shares) · bought $17.6M and sold $40.2MShares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

The set of concentrated managers changed between quarters: with the set as it was then, 7 held it last quarter (the chart point); with today's set, 6 (the base for the change).

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Largest holders of DBVT (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Fundamentals

12-month figures to Sep 30, 2026 · balance sheet as of Sep 30, 2026.

Profitability
Operating margin
—
Net margin
—
ROE
-139.5%
Growth
Revenue (TTM)
$3.7M
Revenue growth
-32.2%
Net income (TTM)
$-207M
Balance sheet
Net debt / EBITDA
—
Free cash flow (TTM)
$-192M
Quality vs sector
—

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Shares outstanding: buybacks and dilution

Diluted shares by fiscal year (split-adjusted)

2025: 139.6 M

139.6 M0
20212025
1 year
+43.9%
3 years
+80.4%
5 years
no data
Buybacks (FY 2025)
no data
Share issuance
$276M
Stock-based compensation
$5.4M95.6% of revenue
Dividends paid
no data

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
no datanot calculated with negative net income
Interest coverage (operating income ÷ interest)
no data
Debt due within 12 months
no data

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
0
Amount (6 m)
$0
CEO/CFO bought (12 m)
No

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

  • Jun 5, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • May 5, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow DBVT for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow DBVT